Blog
RSS FeedPosted by Michael Wonder on 27 Apr 2023
CADTH, ICER, and NICE release joint position statement on redacting clinical data awaiting publication
24 April 2023 - The position statement is a step toward greater transparency of unpublished data and a tangible outcome ...
Posted by Michael Wonder on 11 Nov 2022
CADTH launches consultation on real world evidence reporting guidance
10 November 2022 - Today, CADTH, on behalf of the Real World Evidence Steering Committee, launched a public consultation to ...
Posted by Michael Wonder on 01 Aug 2019
Proposal to enhance the transparency of CADTH’s review reports and recommendations
31 July 2019 - CADTH is committed to increasing the transparency of its health technology assessment processes. ...
Posted by Michael Wonder on 29 May 2019
Prices of Canadian generic medicines below international average
29 May 2019 - PMRPB: Canadian price declines steepest of all OECD countries. ...
Posted by Michael Wonder on 23 Apr 2019
Additional embargo period following revised CDEC recommendations
17 April 2019 - Effective immediately, CADTH has revised its procedures for the CADTH Common Drug Review to permit an ...
Posted by Michael Wonder on 13 Nov 2018
Canada's HTA agency releases report on international biosimilar policies
8 November 2018 - The Canadian Agency for Drugs and Technologies in Health (CADTH), the Canadian entity responsible for health ...
Posted by Michael Wonder on 16 Apr 2018
CADTH 2018-2021 strategic plan
16 April 2018 - Dr. Brian O’Rourke, CADTH President and CEO, has released the CADTH 2018-2021 Strategic Plan. ...
Posted by Michael Wonder on 27 Mar 2018
Gene therapy: international regulatory and health technology assessment activities and reimbursement status
28 March 2018 - There is widespread variation in the definition of gene therapy used by international regulatory bodies and a ...
Posted by Michael Wonder on 07 Feb 2018
Canadian generic drug prices higher than international levels in recent years
6 February 2018 - The Patented Medicine Prices Review Board releases its latest report on generic drug pricing in Canada. ...
Posted by Michael Wonder on 02 Oct 2017
Revised procedure for advance notification of pending CDR submissions and resubmissions
28 September 2017 - In September 2016, CADTH updated the advance notification procedure for the Common Drug Review. ...
Posted by Michael Wonder on 15 Aug 2017
Posting of key milestones for CDR projects
14 August 2017 - Key milestones for CDR submissions, resubmissions, and requests for advice will now be posted within the ...
Posted by Michael Wonder on 01 Aug 2017
Sharing patient input submissions for the CDR program
1 August 2017 - Since February 2014, CADTH has shared patient input submissions on our website, when permission has been ...
Posted by Michael Wonder on 16 Mar 2017
Call for feedback: new drugs for type 2 diabetes: second-line therapy : a therapeutic review update
15 March 2017 - A report on new drugs for second-line therapy for 2 diabetes: a therapeutic review update is now ...
Posted by Michael Wonder on 15 Mar 2017
New CADTH guidelines for the economic evaluation of health technologies
15 March 2017 - Join CADTH in person or online on Tuesday, 28 March 2017 as they release the fourth ...
Posted by Michael Wonder on 22 Jan 2017
Call for feedback on a therapeutic review update of new second-line therapies for type 2 diabetes mellitus
20 January 2017 - Two draft science reports on new drugs for type 2 diabetes: second-line therapy : a therapeutic review ...